Antipsychotic properties of the partial dopamine agonist (-)-3-(3- hydroxyphenyl)-N-n-propylpiperidine (preclamol) in schizophrenia

Biological Psychiatry

Volumn 43, Issue 1, 1998, Pages 2-11

  Lahti, Adrienne C ^a   Weiler, Martin A ^a   Corey, Patricia K ^a   Lahti, Robert A ^a   Carlsson, Arvid ^b   Tamminga, Carol A ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

( ) 3PPP; Antipsychotic; Autoreceptor; Partial dopamine agonist; Schizophrenia

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; PARTIAL AGONIST; PLACEBO; PRECLAMOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SYMPTOM; TREATMENT OUTCOME;

ADULT; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0031963973     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(97)00030-9     Document Type: Article

References (53)

1. Andreasen NC. Negative symptoms of schizophrenia Definitions and reliability . Arch Gen Psychiatry. 39:1982;784-788.
2. Angrist B, Rotrosen J, Gershon S. Responses to apomorphine, amphetamine and neuroleptics in schizophrenic subjects. Psychopharmacology. 67:1980;31-38.
3. Ariens EJ. Intrinsic activity Partial agonists and partial antagonists . J Cardiovasc Pharmacol. 5:(suppl 1):1983;S8-S15.
4. Arnt J. Differential behavioral effects of dopamine agonists in developing rats A study of (-)-3PPP enantioners . Eur J Pharmacol. 91:1983;273-278.
5. Astrachan BM, Harrow M, Adler D, Brauer L, Schwartz A, Schwartz C, Tucker G. A checklist for the diagnosis of schizophrenia. Br J Psychiatry. 121:1972;529-539.
6. Bergstrom DA, Carlson JH, Bromley SD, Jackson DM, Walters JR. Differential electrophysiological effects of (-)-3PPP and its enantioners on dopamine autoreceptors and postsynaptic receptors. Eur J Pharmacol. 124:1986;75-84.
7. Brambilla F, Scarone S, Pugnetti L, Massiromi R, Penati G, Nobile P. Bromocriptine therapy in chronic schizophrenia Effects on symptomatology, sleep patterns, and prolactin response to stimulation . Psychiatry Res. 8:1983;159-169.
8. Bunney BS, Aghajanian GK, Roth RH. Comparison of effects of L-dopa, amphetamine, and apomorphine on firing rate of rat dopaminergic neurons. Nature. 245:1973;123-125.
9. Cannon-Spoor HE, Potkin SP, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull. 8:1982;470-484.
10. Carlsson A. Dopaminergic autoreceptors. Almgren A, Carlsson A, Engel J. Chemical Tools in Catecholamine Research. vol II:1975;219-224 North Holland, Amsterdam.
11. Cassady SL, Thaker GK, Summerfelt A, Tamming CA. The Maryland Psychiatric Research Center scale and the characterization of involuntary movements. Psychiatry Res. 70:1997;21-37.
12. 2 dopamine receptors . Mol Pharmacol. 45:1994;51-60.
13. Clark D, Hjorth S, Carlsson A. Dopamine-receptor agonists Mechanisms underlying autoreceptor selectivity: I. Review of the evidence . J Neural Transm. 62:1985;1-52.
14. Clark D, Hjorth S, Carlsson A. Dopamine-receptor agonists Mechanisms underlying autoreceptor selectivity: II. Theoretical considerations . J Neural Transm. 62:1985;171-207.
15. Corsini GU, DelZompo M, Manconi S, Cianchetti C, Mangoni A, Gessa GL. Sedative, hypnotic and antipsychotic effects of low doses of apomorphine in man. Adv Biochem Psychopharmacol. 16:1977;645-649.
16. Corsini CU, Piccardi MP, Bocchetta A, Bernardi F, DelZompo M. Behavioral effects of apomorphine in man Dopamine receptor implications . Gessa GL, Corsini FV. Apomorphine and Other Dopaminomimetics. vol II:1981;13-24 Raven Press, New York.
17. Delay J, Deniker P (1952): Trente-huit cas de psychoses traitees par la cure prolongee et continue de 4500 R.P. [Thirty eight cases of psychosis treated by chronic treatment with 4500 R.P.]. Edited by Masson P Luxembourg. Congres des Medecins Alienistes et Neurologistes de France. pp 497-502.
18. Ferrier IN, Johnstone EC, Crow TJ. Clinical effects of apomorphine in schizophrenia. Br J Psychiatry. 144:1984;341-348.
19. Hjorth S, Carlsson A, Clark D, et al. Central dopamine receptor agonist and antagonist actions of the enantiomers of (-)-3PPP. Psychopharmacology. 81:1983;89-99.
20. Jeste DV, Zalcman S, Weinberger DR, et al. Apomorphine response and subtyping of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 7:1983;83-88.
21. Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull. 22:1986;254-258.
22. Kehr W, Carlsson A, Lindquist M. Evidence for a receptor mediated feedback control of striatal tyrosine hydroxylase activity. J Pharm Pharmacol. 24:1972;744-747.
23. Kenakin TP. Efficacy in Pharmacologic Analysis of Drug Receptor Interaction. 1993;249-277 Raven Press, New York.
24. Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT. The schedule for the deficit syndrome An instrument for research in schizophrenia . Psychiatry Res. 30:1989;119-123.
25. Klein DF, Davis JM. Diagnosis and Drug Treatment of Psychiatric Disorders. 1969;61-63 Williams and Wilkins, Baltimore.
26. 2 guanine nucleotide-binding protein-coupled receptor Utilization of receptor state binding affinities . Mol Pharmacol. 42:1992;432-438.
27. 4.4 receptors. Eur J Pharmacol. 301:1996;R11-R13.
28. Levy MI, Davis BM, Mohs RC, et al. Apomorphine and schizophrenia Treatment, CSF, and neuroendocrine responses . Arch Gen Psychiatry. 41:1984;520-524.
29. Meltzer HY. Relevance of dopamine autoreceptors for psychiatry Preclinical and clinical studies . Schizophr Bull. 6:1980;456-475.
30. Meltzer LT, Christoffersen CL, Corbin AE, et al. CI-1007, a dopamine partial agonist and potential antipsychotic agent II. Neurophysiological and behavioral effects . J Pharmacol Exp Ther. 274:1995;912-920.
31. 2 agonist in the treatment of negative symptoms of chronic schizophrenia. Biol Psychiatry. 33:1993;687-693.
32. Olbrich R, Schanz H. The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics. Pharmacopsychiatry. 21:1988;384-390.
33. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 10:1962;799-812.
34. Pirtosek Z, Merello M, Carlsson A, Stern G. Preclamol and parkinsonian fluctuations. Clin Neuropharmacol. 16:1993;550-554.
35. Potkin SG (1996): Partial Dopamine Agonist Symposium. Collegium Internationale Neuro-Psychopharmacologicum (CINP), Melbourne, Australia.
36. Potkin SG, Anand R. A partial dopamine agonist SDZHDC912 has antipsychotic efficacy. Sandoz Collaborating Centers [abstract]. Schizophr Res. 9:1993;247.
37. Pugsley TA, Davis MD, Akunne HC, et al. CI-1007, a dopamine partial agonist and potential antipsychotic agent I. Neurochemical effects . J Pharmacol Exp Ther. 274:1995;898-911.
38. Roth RH. Dopamine autoreceptors Pharmacology, function and comparison with postsynaptic dopamine receptors . Commun Psychopharmacol. 3:1979;429-445.
39. Skirboll LA, Grace AA, Bunney BS. Dopamine auto- and postsynaptic receptors Electrophysiological evidence for differential sensitivity to dopamine agonists . Science. 206:1979;80-82.
40. Smith RC, Tamminga CA, Davis JM. Effect of apomorphine on schizophrenic symptoms. J Neural Transm. 40:1977;171-176.
41. Spitzer RL, Williams JBW, Gibbon M. Structured Clinical Interview for DSM III-R (SCID). 1987;New York State Psychiatric Institute, Biometrics Research Department, New York.
42. Strauss JS, Carpenter WT. The prediction of outcome in schizophrenia. Arch Gen Psychiatry. 31:1974;37-42.
43. Svensson L, Ahlenius S. Suppression of exploratory activity in the rat by the local application of 3-PPP enantiomers into nucleus accumbens. European Journal of Pharmacology. 88:1983;393-397.
44. Tamminga CA, Schaffer MH. Treatment of schizophrenia with ergot derivatives. Psychopharmacology. 66:1979;239-242.
45. Tamminga CA, Shaffer MH, Smith RC, Davis JM. Schizophrenic systems improve with apomorphine. Science. 200:1978;567-568.
46. Tamminga CA, Gotts MD, Thaker GK, et al. Dopamine agonist treatment of schizophrenia with N-propylnorapomorphine. Arch Gen Psychiatry. 43:1986;398-402.
47. Tamminga CA, Cascella NG, Lahti RA, Lindberg M, Carlsson A. Pharmacologic properties of (-)-3PPP (preclamol) in man. J Neural Transm Gen Sect. 88:1992;165-175.
48. Toru M (1996): Partial Dopamine Agonist Symposium. Collegium Internationale Neuro-Psychopharmacologicum (CINP), Melbourne, Australia.
49. Metman L, Sethy VH, Roberts JR, et al. Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease. Mov Disord. 9:1994;577-581.
50. Walters JR, Roth RH. Pre- and postsynaptic actions of antipsychotic drugs. Sedvall G, Uvmas B. Antipsychotic Drugs Pharmacodynamics and Pharmacokinetics . 1975;147-159 Pergamon Press, New York.
51. Walters JR, Roth RH. Dopaminergic neurons An in vivo system for measuring drug interactions with presynaptic receptors . Naunyn-Schmiedeberg's Arch Pharmacol. 296:1976;5-14.
52. Walters JR, Bunney BS, Roth RH. Piribedil and apomorphine Pre- and postsynaptic effects on dopamine synthesis and neuronal activity . Adv Neurol. 9:1975;273-284.
53. Wetzel H, Hillert A, Grunder G, Benkert O. Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms. Am J Psychiatry. 191:1994;1499-1502.